The Navitoclax Diaries
Scientists feel that combining navitoclax with ruxolitinib should help those with myelofibrosis. On this trial 50 % the individuals have navitoclax and ruxolitinib. One other 50 % have ruxolitinib plus a dummy drug (placebo ).-values) for each analyzed gene and protein expression amongst diverse experimental and Regulate teams. Pearson correlation